The pharmacologic approach to airway clearance: Mucoactive agents

Paediatric Respiratory Reviews

Volumn 7, Issue SUPPL. 1, 2006, Pages

  Rubin, Bruce K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

cough clearance; expectorant; mucoactive medications; mucociliary clearance; mucokinetics; mucolytics; mucoregulatory; surfactant

Indexed keywords

ACETYLCYSTEINE; ACETYLCYSTEINE DERIVATIVE; ANTIBIOTIC AGENT; ATROPINE; ATROPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXTRAN; DORNASE ALFA; ERYTHROMYCIN; EXPECTORANT AGENT; GELSOLIN; GLUCOCORTICOID; GLYCEROL; GUAIFENESIN; INDOMETACIN; IPRATROPIUM BROMIDE; LOW MOLECULAR WEIGHT HEPARIN; MACROLIDE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; NUCLEOTIDE; RESPIRATORY TRACT AGENT; SODIUM CHLORIDE; SURFACTANT; THYMOSIN BETA4; TIOTROPIUM BROMIDE; UNINDEXED DRUG;

BRONCHIOLITIS; BRONCHOSPASM; CHRONIC BRONCHITIS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; FLUSHING; HUMAN; HYDRATION; LUNG CLEARANCE; LUNG DISEASE; MUCUS SECRETION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA;

EXPECTORANTS; HUMANS; MUCOCILIARY CLEARANCE; MUCUS; RESPIRATORY TRACT DISEASES; TREATMENT OUTCOME;

EID: 33745223269     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2006.04.198     Document Type: Review

References (31)

1. Rubin B.K., Tomkiewicz R.P., and King M. Mucoactive agents: old and new. In: Wilmott R.W. (Ed). The Pediatric Lung (1997), Birkhäuser Publishing, Basel 155-179
2. In: Rubin B.K., and van der Schans C.P. (Eds). Therapy for Mucus Clearance Disorders. Biology of the Lung Series, Claude Lenfant (NIH) Executive editor (2004), Marcel Dekker
3. Jager E.G. Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients. Clinical Therapeutics 11 (1989) 341-362
4. Shim C., King M., and Williams Jr. M.H. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 92 (1987) 679-682
5. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2005. CD001506.
6. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2002. CD002996.
7. Suri R., Metcalfe C., Lees B., et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 358 (2001) 1316-1321
8. Graham A., Hashani A., Alton E.W., et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 6 (1993) 1243-1248
9. Noone P.G., Hamblett N., Accurso F., et al. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol 32 (2001) 122-128
10. Deterding R., Retsch-Bogart G., Milgram L., et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 39 (2005) 339-348
11. Henke M.O., Renner A., Huber R.M., Seeds M.C., and Rubin B.K. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 31 (2004) 86-91
12. Tomkiewicz R.P., Kishioka C., Freeman J., and Rubin B.K. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G. (Ed). Cilia, Mucus and Mucociliary Interactions (1998), Marcel Dekker, New York 333-341
13. King M., and Rubin B.K. Mucus rheology: Relationship with transport. In: Takishima T. (Ed). Chapter 7 in Airway secretion: Physiological Bases for the Control of Mucus Hypersecretion (1994), Marcel Dekker, Inc, New York 283-314
14. Puchelle E., Zahm J.M., Girard F., Bertrand A., Polu J.M., Aug F., and Sadoul P. Mucociliary transport in vivo and in vitro. Relations to sputum properties in chronic bronchitis. Eur J Respir Dis 61 (1980) 254-264
15. Rubin B.K., MacLeod P.M., Sturgess J.M., and King M. Recurrent respiratory infections in a child with fucosidosis: Is the mucus too thin for effective transport?. Pediatr Pulmonol 10 (1991) 304-309
16. Grandjean E.M., Berthet P., Ruffmann R., and Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22 (2000) 209-221
17. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 365 (2005) 1552-1560
18. Laube B.L., Auci R.M., Shields D.E., et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 153 (1996) 752-760
19. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331 (1994) 637-642
20. Rubin B.K. Who will benefit from DNase?. Pediatric Pulmonology 27 (1999) 3-4
21. Feng W., Garrett H., Speert D.P., and King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med 157 (1998) 710-714
22. Isawa T., Teshima T., Hirano T., Ebina A., and Konno K. Effect of oral salbutamol on mucociliary clearance mechanisms in the lungs. Tohoku J Experimental Med 150 (1986) 51-61
23. King M., Brock G., and Lundell C. Clearance of mucus by simulated cough. J Appl Physiol 58 (1985) 1776-1782
24. Hite RD, Seeds MC, Jacinto RB, Balasubramanian R, Waite M, Bass D. Hydrolysis of surfactant-associated phosphotidylcholine by mammalian secretory phospholipases A2. Am J Physiol 1998: 275 (Lung Cell Mol Physiol 19): L740-L747.
25. Anzueto A., Jubran A., Ohar J.A., et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial. J Am Med Assoc 278 (1997) 1426-1431
26. Tamaoki J., Chiyotani A., Kobayashi K., Sakai N., Kanemura T., and Takizawa T. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 145 (1992) 548-552
27. Tamaoki J., Chiyotani A., Tagaya E., Sakai N., and Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 49 (1994) 545-548
28. Shinkai M., and Rubin B.K. A global perspective on macrolide use. Japanese J Antibiotics 58 (2005) 129-132
29. Shinkai M., Park C.S., and Rubin B.K. Immunomodulatory effects of macrolide antibiotics. Clin Pulm Med 12 (2005) 341-349
30. Jaffé A., and Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatric Pulmonology 31 (2001) 464-473
31. In: Rubin B.K., and Tamaoki J. (Eds). Antibiotics as Anti-inflammatory and Immunomodulatory Agents (2004), Birkhäuser Verlag AG, Basel